SCHEMBL4147254

SCHEMBL4147254

NC(=O)c1ccccc1C[CH]c1cc(-c2ccc3c(N)n[nH]c3c2)c(Cl)s1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.40
MKNK1 Q9BUB5 4/20 0.39
MKNK2 Q9HBH9 4/20 0.39
PDPK1 O15530 2/20 0.38
AURKA O14965 1/20 0.38
TGFBR1 P36897 1/20 0.38
AURKB Q96GD4 1/20 0.38
KDR P35968 4/20 0.37
JAK1 P23458 2/20 0.37
TYK2 P29597 2/20 0.37
JAK3 P52333 2/20 0.37
SGK1 O00141 2/20 0.37
SCN5A Q14524 1/20 0.37
SCN9A Q15858 1/20 0.37
PAK1 Q13153 1/20 0.36
GSK3B P49841 1/20 0.36
ABL1 P00519 2/20 0.35
BCR P11274 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140352 0.83 JAK2 (0.45) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL3166853 0.82 JAK2 (0.42) JAK2MKNK1MKNK2KDRJAK1
SCHEMBL3172972 0.79 CHEK1 (0.43) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL3166844 0.79 KDR (0.42) JAK2MKNK1MKNK2PDPK1KDR
SCHEMBL3168792 0.79 JAK2 (0.50) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL3546324 0.78 F11 (0.47) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL3173793 0.78 JAK2 (0.46) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL3174551 0.77 PDPK1 (0.46) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL4798614 0.77 PDPK1 (0.47) JAK2MKNK1MKNK2PDPK1AURKA
SCHEMBL3175009 0.76 JAK2 (0.44) JAK2MKNK1MKNK2PDPK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466295-B2 Thiophene derivatives as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-06-18 US claimed
US-20090253766-A1 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US claimed
US-8466295-B2 Thiophene derivatives as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-06-18 US disclosed
US-20090253766-A1 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2007070816-A2 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253766-A1 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS TFPI, F12, F11 JAK2 641/4885MKNK1 1432/4885MKNK2 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.